Immix Biopharma Inc IMMX Stock Analysis
- Nasdaq
- Stock
- Market open · no trades yet today
$7.20 down $0.77, 9.66% at close Nov 5
Last close · Previous close $7.97
- Market cap
- At the Nov 5 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.88Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$7.20down $0.77, 9.66%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$7.97Nov 4
- Volume1.41MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.25MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.89 to $15.10; now $7.20
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
IMMX beat the S&P 500 in 3 of 5 periods.
| Period | IMMX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IMMX: down 28.9% S&P 500: down 5.4% | IMMX trailed the S&P 500 by 23.5 percentage points Trailed |
| 3M | IMMX: down 24.5% S&P 500: down 4.5% | IMMX trailed the S&P 500 by 20.0 percentage points Trailed |
| YTD | IMMX: up 37.7% S&P 500: up 8.3% | IMMX beat the S&P 500 by 29.4 percentage points Beat |
| 1Y | IMMX: up 136.1% S&P 500: up 9.3% | IMMX beat the S&P 500 by 126.8 percentage points Beat |
| Long term | ||
| 3Y | IMMX: up 101.7% S&P 500: up 74.8% +26.3% vs +20.5% a year | IMMX beat the S&P 500 by 26.9 percentage points Beat |
$10,000 invested in IMMX a year ago (Nov 5, 2025) would be worth about $23,607 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $10,934.
IMMX beat the S&P 500 in 3 of 5 periods.
| Period | IMMX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IMMX: down 28.9% S&P 500: down 5.4% | IMMX trailed the S&P 500 by 23.5 percentage points Trailed |
| 3M | IMMX: down 24.5% S&P 500: down 4.8% | IMMX trailed the S&P 500 by 19.7 percentage points Trailed |
| YTD | IMMX: up 37.7% S&P 500: up 7.5% | IMMX beat the S&P 500 by 30.2 percentage points Beat |
| 1Y | IMMX: up 136.1% S&P 500: up 8.2% | IMMX beat the S&P 500 by 127.9 percentage points Beat |
| Long term | ||
| 3Y | IMMX: up 101.7% S&P 500: up 68.6% +26.3% vs +19.0% a year | IMMX beat the S&P 500 by 33.1 percentage points Beat |
$10,000 invested in IMMX a year ago (Nov 5, 2025) would be worth about $23,607 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,818.
All-time high
$14.47
Closing high on . Now 50.2% below that record.
Split-adjusted daily closes since Dec 16, 2021.
Stock splits
IMMX hasn’t split since its price history begins in 2021.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$39.92M
- Diluted EPS
- −$0.88
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$7.15M | −$0.24 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$4.81M | −$0.16 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$4.54M | −$0.15 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$6.62M | −$0.22 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$7.59M | −$0.24 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$10.69M | −$0.28 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$10.09M | −$0.18 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$11.56M | −$0.18 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$24.38M | −$6.64 |
| FY22 (Dec 31, 2022) | $0.00 | −$8.23M | −$0.59 |
| FY23 (Dec 31, 2023) | $0.00 | −$15.43M | −$0.89 |
| FY24 (Dec 31, 2024) | $0.00 | −$21.61M | −$0.76 |
| FY25 (Dec 31, 2025) | $0.00 | −$29.44M | −$0.89 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$39.09MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$38.50MLast 12 months
- Capital spending$591.11KLast 12 months
Shareholder returns
- $261.66MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $234.16MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$1.00MAs of Jun 30, 2026
- Net cash$233.16MAs of Jun 30, 2026
- 25.13As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −38.4%Last 12 months
Over the last 12 months, Immix Biopharma lost money: its net loss was 38.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −34.7%Last 12 months
Over the last 12 months, Immix Biopharma’s net loss was 34.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Immix Biopharma Inc
Immix Biopharma, Inc. (ImmixBio) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2 trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity of any kind in AL Amyloidosis and short duration of cytokine release syndrome (CRS), supporting expansion into select immune-mediated diseases. NXC-201 has been awarded Orphan Drug Designation (ODD) in AL Amyloidosis by the US FDA and in the EU by the EMA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
IMMX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IMMX stock FAQ
What is IMMX stock’s price today?
Immix Biopharma (IMMX) traded at $7.20 at the close on , down $0.77 (9.66%) from the previous close of $7.97. Over the past 52 weeks it has traded between $2.89 and $15.10.
What is IMMX’s P/E ratio?
IMMX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.88).
What are IMMX’s earnings per share?
IMMX’s diluted earnings per share were −$0.88 over the four quarters to , compared with −$0.77 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.18 per share, against −$0.22 a year earlier (how EPS works).
Does IMMX pay a dividend?
Immix Biopharma hasn’t paid a dividend in the last twelve months.
What is IMMX’s 52-week high and low?
Over the past 52 weeks IMMX has traded as low as $2.89 and as high as $15.10. At $7.20 at the close on , it is 52.3% below that high and 149.1% above the low.
What is IMMX’s all-time high?
IMMX’s highest closing price was $14.47 on , adjusted for stock splits. At $7.20 at the close on , it is 50.2% below that record.
Has IMMX stock ever split?
No. IMMX hasn’t split since its price history begins in 2021.
How has IMMX stock performed?
Including dividends and measured to the close on , IMMX has returned +37.7% so far this year and +136.1% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.3% and +9.3%. Past performance doesn’t predict future returns.
What sector and industry is Immix Biopharma in?
Immix Biopharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does IMMX trade on?
Immix Biopharma trades on the Nasdaq under the ticker symbol IMMX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.